Arcutis and Sato Pharma collaborate on topical roflumilast in Japan for inflammatory skin diseases, with Arcutis receiving $25M upfront.

Arcutis Biotherapeutics and Sato Pharmaceutical Co. have entered into a strategic collaboration and licensing agreement for topical roflumilast in Japan. Arcutis will receive $25M upfront, plus potential milestone payments and royalties. The collaboration aims to offer a non-steroidal topical option for Japanese patients with inflammatory skin diseases such as plaque psoriasis, seborrheic dermatitis, and atopic dermatitis.